KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Common Equity: 2009-2024

Historic Common Equity for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $29.4 billion.

  • Regeneron Pharmaceuticals' Common Equity rose 5.56% to $31.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $31.0 billion, marking a year-over-year increase of 5.56%. This contributed to the annual value of $29.4 billion for FY2024, which is 13.02% up from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Common Equity stood at $29.4 billion for FY2024, which was up 13.02% from $26.0 billion recorded in FY2023.
  • Over the past 5 years, Regeneron Pharmaceuticals' Common Equity peaked at $29.4 billion during FY2024, and registered a low of $11.0 billion during FY2020.
  • Moreover, its 3-year median value for Common Equity was $26.0 billion (2023), whereas its average is $26.0 billion.
  • Per our database at Business Quant, Regeneron Pharmaceuticals' Common Equity dropped by 0.58% in 2020 and then spiked by 70.23% in 2021.
  • Over the past 5 years, Regeneron Pharmaceuticals' Common Equity (Yearly) stood at $11.0 billion in 2020, then spiked by 70.23% to $18.8 billion in 2021, then grew by 20.75% to $22.7 billion in 2022, then rose by 14.60% to $26.0 billion in 2023, then grew by 13.02% to $29.4 billion in 2024.